Sunday Night Radar: (MYNZ) Will Be Topping Tomorrow’s Watchlist—Here’s Why

*Sponsored Krypton Street Announces Coverage On Mainz Biomed (NASDAQ: MYNZ) — Starting Tomorrow Morning, Monday, April 28, 2025. Here’s What We Can Tell You—So Far… On April 17, 2025, A Biotech Analyst At Maxim Group Set A $14 Target On (MYNZ), Which Suggests Over 330% Upside Potential From Recent Levels. Fewer Than 3M Shares Listed Gives (MYNZ) A Tight Float That Could Lead To The Potential For Significant Swings If Demand Begins To Shift. In Just Eight Sessions Between April 4 And April 15, 2025, (MYNZ) Quietly Moved Approximately 33%, From $2.65 To $3.54. This Past Friday, (MYNZ) Triggered 15 Bullish Signals On TradingView’s 15-Minute Technical Dashboard, Including the Momentum Indicator. Pull (MYNZ) Before Tomorrow Morning… April 27, 2025 Dear Reader, In an era defined by speed, screens, and smart devices, it’s easy to forget how silent some threats remain—until it’s too late. But inside a modest lab in Mainz, Germany, a quiet revolution is unfolding.  One that doesn’t rely on fanfare or headlines, but on data, diagnostics, and a bold reimagining of early detection—starting where it matters most. Mainz Biomed (NASDAQ: MYNZ) isn’t building the next mobile app or wearable gadget.  It’s focused on something far more elemental: a practical, at-home diagnostic tool designed to catch colorectal cancer—still the second leading cause of cancer death worldwide—before it turns deadly. And yet, its science isn’t the only thing drawing new attention. With a market cap under $11M and fewer than 3M shares listed in its float, (MYNZ) remains sharply under the radar.  Companies this lean don’t often stay quiet for long—especially when momentum starts to build. In just eight sessions, (MYNZ) quietly advanced approximately 33%, moving from $2.65 on April 4 to $3.54 by April 15.  As of now, it’s trending above two key moving averages: its 5-day at $3.19 and 20-day at $3.23.  With the 50-day at $4.34, the 100-day at $4.97, and the 200-day at $8.64, we’re keeping all eyes on what could be a developing technical situation. On Friday, (MYNZ) triggered 15 bullish signals on TradingView’s 15-minute technical dashboard, including its momentum indicator.   Just days before, on April 17, biotech analyst Michael Okunewitch of Maxim Group set a $14 target—suggesting over 330% upside from Friday’s open of $3.24. With that momentum building, (MYNZ) has officially landed on our radar.  And tomorrow—Monday, April 28, 2025—it will be topping our watchlist. Their lead product, ColoAlert®, paired with a decentralized testing model that empowers everyday labs across the U.S., is quietly reshaping what screening can look like in this decade. And now, the company is being watched closely—not just for what it’s built, but for where it’s headed next. The Case for a Closer Look Mainz Biomed N.V. (NASDAQ: MYNZ)’s case is grounded in both scientific rigor and strategic momentum.  At the core of its current offering is ColoAlert®, a flagship screening test that combines stool-based PCR diagnostics with FIT technology to detect tumor DNA.  With 85% sensitivity and 92% specificity, the test is designed to catch signals early and clearly—something reinforced by a 98% satisfaction rate among users surveyed.  In late 2024, the company strengthened its foundation through high-profile partnerships with Thermo Fisher Scientific and Quest Diagnostics.   Thermo Fisher is supporting the development of Mainz’s next-generation assay by providing tools and resources, while Quest is preparing to serve as a key partner for U.S.-based clinical trials. As of early 2025, industry watchers have been paying closer attention to (MYNZ)’s progress, especially in anticipation of its large-scale U.S. study, reconAAsense, which will evaluate the platform across 15,000 average-risk individuals.  Results from earlier pooled studies already show 82% sensitivity for advanced adenomas—an area where many current diagnostics fall short.  Adding to its differentiation, (MYNZ) has moved away from the centralized CLIA lab model that dominates the industry.  Instead, its decentralized approach allows qualified labs across the U.S. to process samples independently, enabling faster deployment and broader reach without the overhead of centralized infrastructure. The company’s leadership team, headed by CEO Guido Baechler and composed of veterans from Roche, Qiagen, and Abbott, brings deep diagnostics expertise to the table.  Their collective experience is supported by a Medical Advisory Board that includes top minds in oncology and molecular testing.  Looking ahead, (MYNZ) is preparing for what could be its most ambitious chapter yet: early detection of pancreatic cancer.  In collaboration with Liquid Biosciences, the company is advancing a blood-based mRNA test that has already demonstrated 95% sensitivity and 98% specificity in early validation—a potential leap forward in detecting one of the most challenging cancers in clinical practice. Recent Developments Behind the headlines, Mainz Biomed (NASDAQ: MYNZ) is making measured progress on multiple fronts.  In 2024, revenue from its lab partner network rose 33% year over year, while operating loss dropped 30% and net loss fell 18%, reflecting a tighter strategic focus. The company secured a collaboration with Thermo Fisher Scientific to help develop and potentially commercialize its next-generation mRNA-based colorectal screening test.  In parallel, a new agreement with Quest Diagnostics supports its pivotal reconAAsense trial, which will enroll 15,000 average-risk patients across the U.S. Performance data continues to validate the company’s platform, with results presented at DDW and ASCO showing 97% sensitivity for colorectal cancer and 82% for advanced lesions—including 100% detection of high-grade dysplasia. (MYNZ) also raised $8M in a follow-on offering, regained full Nasdaq compliance, and launched its eAArly DETECT 2 feasibility study—on track for a topline readout by year-end. Meanwhile, its expanded partnership with Liquid Biosciences is advancing a blood-based pancreatic cancer test, showing early validation of 95% sensitivity and 98% specificity. A Pivotal Moment, a Clearer Direction Over the past year, (MYNZ) has narrowed its attention to clinical execution. Its large-scale reconAAsense trial will be a cornerstone event—designed to validate their next-generation test for the U.S. market and support FDA approval.  At the same time, they’re reducing operational costs and streamlining partnerships, ensuring that scientific progress is matched by operational efficiency. With a powerful diagnostic platform, proven test performance, strategic partnerships in place, and a large-scale U.S. trial underway, (MYNZ) is operating in a space that touches countless lives every year—and one that continues to grow in urgency and relevance. This isn’t a brand that shouts.  But for those following innovation at the crossroads of clinical data and practical application, it’s one little-known company to keep an eye on. 7 Reasons Why Mainz Biomed (NASDAQ: MYNZ) Will Be Topping Our Watchlist Tomorrow Morning—Monday, April 28, 2025… 1. Extremely Low Float: With fewer than 3M shares listed, (MYNZ) has a very tight float, which could lead to the potential for significant swings if demand begins to shift. 2. Strong Analyst Coverage: Recently, on April 17, 2025, a biotech analyst at Maxim Group set a $14 target on (MYNZ), which suggests an upside potential of over 330%. 3. Recent Market Recognition: In just eight sessions between April 4 and April 15, 2025, (MYNZ) quietly moved approximately 33%, from $2.65 to $3.54. 4. Bullish Technical Signals: Just this past Friday, (MYNZ) triggered 15 positive indicators on TradingView’s technical dashboard (15-minute timeframe), including momentum signals that many short-term market watchers monitor closely. 5. Building Strategic Partnerships: (MYNZ) has entered high-profile collaborations with Thermo Fisher Scientific and Quest Diagnostics, aligning itself with industry giants to develop and expand its next-generation diagnostic platforms. 6. Improved Positioning: In 2024, (MYNZ) increased lab network revenue by 33%, while simultaneously cutting its operating loss by 30% and net loss by 18%, demonstrating disciplined growth and sharper operational focus. 7. Clinical Milestones Ahead: The company is advancing its pivotal reconAAsense trial, targeting 15,000 participants across the U.S., while early data from its next-generation tests continue to show high sensitivity rates in detecting colorectal cancer and precancerous conditions. Pull Up (MYNZ) Before Tomorrow Morning… With a razor-thin float, expanding partnerships, improving financials, and a pivotal trial in progress, Mainz Biomed (NASDAQ: MYNZ) is showing the kind of activity that often precedes broader awareness.  Technical signals are flashing, analysts are starting to weigh in, and the company’s leadership continues to move with strategic precision. We will have all eyes on (MYNZ) tomorrow morning. Consider taking a look at (MYNZ) before you shut it down for the night. Also, keep a lookout for my early morning update. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 04/27/2025 and ending on 04/28/2025 to publicly disseminate information about (MYNZ:US) via digital communications. Under this agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC and their member own shares of (MYNZ:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/mynz-zr9ty/#details

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice